This article was originally published in Bloomberg Law. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors' opinions only.
In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price.
Courts around the country continue to disagree on the causation standard to be applied in False Claims Act cases based on alleged Anti-Kickback Statute violations.
On May 17, 2023, the Federal Trade Commission (FTC) challenged Amgen Inc.’s (Amgen) proposed acquisition of Horizon Therapeutics plc (Horizon). The complaint is significant in three.
In the institution decision for Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc., IPR2022-01225, Paper 21 (P.T.A.B. Jan. 11, 2023), the Patent Trials & Appeals Board ("the Board").